DGAP-News: WILEX AG: WILEX Inc. and Nuclea Biotechnologies Inc. announce cooperation
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: WILEX Inc. and Nuclea Biotechnologies Inc. announce
cooperation
20.03.2013 / 07:12
---------------------------------------------------------------------
PRESS RELEASE
WILEX Inc. and Nuclea Biotechnologies Inc. announce cooperation
- Nuclea will use the WILEX Inc. IVD ELISA for testing the serum
HER-2/neu level in metastatic breast cancer patients
Munich, Germany / Pittsfield, USA, 20 March 2013 WILEX AG (ISIN
DE0006614720/ WL6 / FSE) today announced a partnership between its US
subsidiary WILEX Inc., Cambridge, MA, USA, and Nuclea Biotechnologies,
Inc., Pittsfield, MA, USA, (Nuclea) for the commercialisation of the serum
HER-2/neu (blood) ELISA test. The cooperation will greatly advance research
and identification of biomarkers, a vital component in the growing field of
personalised medicine. Financial terms were not disclosed.
Nuclea discovers biomarkers (genes and proteins) and develops diagnostic
assays that can help predict which courses of treatment will be effective
for certain patients, depending on their genetic makeup. Nuclea has the
capability and expertise to perform in vitro diagnostic (IVD) assays in the
area of oncology in a certified laboratory (CLIA) and also has access
through its business relationships with hospitals and research institutions
to patients in need of such tests.
WILEX Inc. specialises in serum based oncoprotein diagnostics and provides
the only FDA cleared and CE marked IVD ELISA test for the measurement of
serum HER-2/neu in the management and monitoring of patients with
metastatic breast cancer. The IVD is reimbursed by insurance companies and
has a unique CPT code 83950. HER-2, Human Epidermal Growth Factor Receptor
2, is a protein which is overexpressed in various cancer types. The serum
HER-2 level is valuable to doctors for monitoring response to therapy and
progression of disease.
By harnessing this powerful IVD and using it in conjunction with other
clinical tests, this joint project could be a significant clinical offering
in the breast cancer field. In April, clinical testing will begin in
Nuclea's newly designed, state-of-the-art laboratory in Pittsfield, and
will allow oncologists greater access to the HER-2/neu ELISA test.
'Nuclea is excited about the new partnership,' said Patrick J. Muraca,
president&CEO of Nuclea. 'Both companies seek to develop new biomarkers
with the goal of making 21st century cancer treatments more personal and
effective. With our combined experience in the production and
commercialisation of biomarkers, it seemed very natural for us to work
together as pioneers in the field of breast cancer.'
Professor Olaf G. Wilhelm, CEO of WILEX Inc. and WILEX AG, commented:
'Since Nuclea understands and focuses on gene and protein expression
profiles in tumours, the serum HER-2 test is an important addition to their
profiling efforts. Besides using our HER-2 ELISA in its CLIA lab Nuclea
will also start R&D and validation of this test in early breast cancer and
possibly other indications.'
About Nuclea
Nuclea Biotechnologies Inc. is headquartered in Pittsfield, MA, with
additional operations in Worcester, MA. Nuclea has developed and is
commercialising eleven unique diagnostic tests for colon, breast, leukemia,
lung and prostate cancer. Nuclea also performs research leading to novel
molecular oncology therapeutics and diagnostics for the pharmaceutical and
biotechnology industries. More information is available at
www.nucleabio.com.
About WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG, Munich, Germany.
The team has many years' experience in developing and manufacturing
biomarker tests for oncology, which are marketed under the brand name
Oncogene Science. The product portfolio includes enzyme-linked
immunosorbent assays (ELISA) and immunohistochemical (IHC) assays for in
vitro diagnostic (IVD) and research use only (RUO). With the aim of
supporting treatment regimens for cancer patients worldwide WILEX Inc.
offers biomarker tests for measuring oncogenes, growth factor receptors
(HER-2/neu, EGFR), proteases and protease inhibitors (uPA, PAI-1, TIMP-1),
as well as markers of hypoxia (CAIX). WILEX Inc. is based in Cambridge, MA,
USA and also provides GMP and ISO certified manufacturing services. More
information is available at www.oncogene.com.
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer based on antibodies and small molecules. The subsidiary
Heidelberg Pharma GmbH offers preclinical contract research services and an
antibody drug conjugate (ADC) technology platform. The business model
comprises research and product development as well as the commercialisation
of its activities. Our customers and partners include leading international
pharmaceutical companies. WILEX AG is listed at the Frankfurt Stock
Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is
available at www.wilex.com.
ContactThis communication contains certain forward-looking statements relating to
WILEX AG Nuclea Biotechnologies Inc.
Corporate Communications Media Relations
Katja Arnold (CIRO) Greg D'Agostino
Grillparzerstr. 10 Cell +1 617.388.6477
81675 Munich, Germany Office +1 617.695.0369
Tel.: +49 (0)89-41 31 38-126 Email: greg(at)libertysquaregroup.com
Email: investors(at)wilex.com
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
20.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
204455 20.03.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.03.2013 - 07:12 Uhr
Sprache: Deutsch
News-ID 241141
Anzahl Zeichen: 10121
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG: WILEX Inc. and Nuclea Biotechnologies Inc. announce cooperation"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
